4-(1H-苯并咪唑-2-基)-哌嗪-1-羧酸叔丁酯 | 295341-56-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 4-(1H-苯并咪唑-2-基)-哌嗪-1-羧酸叔丁酯
• 中文别名: 萘,1-氟十氢-,(1R,4aR,8aS)-rel-；萘,1-氟十氢-,(1R,4AR,8AS)-REL-
• 英文名称: tert-butyl 4-(1H-benzimidazol-2-yl)piperazine-1-carboxylate
• CAS: 295341-56-9
• 化学式: C₁₆H₂₂N₄O₂
• mdl: MFCD07787276
• 分子量: 302.376
• InChiKey: HFEQYXCCAIHIBP-UHFFFAOYSA-N

物化性质

• 沸点：
  472.6±55.0 °C(Predicted)
• 密度：
  1.231±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  61.5
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-(1H-苯并咪唑-2-基)-哌嗪-1-羧酸叔丁酯 在 盐酸 、 三乙胺 作用下， 以 四氢呋喃 、 1,4-二氧六环 为溶剂， 反应 3.0h， 生成
  参考文献：
  名称：

  Bz-8HQ: a novel supramolecular fluorochrome exhibiting multiple stimuli-responsiveness

  摘要：

  一种新型多功能荧光分子（Bz-8HQ）通过联结苯并咪唑（Bz）和8-羟基喹啉（8HQ）分子合成，并通过光谱学研究了其对多种刺激的响应。

  DOI：

  10.1039/d1nj04998d
• 作为产物：
  描述：

  2-羟基苯并咪唑 在 三氯氧磷 作用下， 以 甲苯 为溶剂， 反应 6.0h， 生成 4-(1H-苯并咪唑-2-基)-哌嗪-1-羧酸叔丁酯
  参考文献：
  名称：

  聚（ADP-核糖）聚合酶抑制剂的设计与合成：腺苷口袋结合基序对3-Oxo-2,3-dihydrobenzofuran-7-boxamide的效力和选择性的影响。

  摘要：

  聚腺苷5'-二磷酸核糖）聚合酶（PARP）抑制剂是一类抗癌药物，可阻断PARP蛋白的催化活性。优化我们的先导化合物1（（Z）-2-亚苄基-3-氧代-2,3-二氢苯并呋喃-7-羧酰胺; PARP-1 IC50 = 434 nM）产生了四唑基类似物（51，IC50 = 35 nM）具有更好的抑制作用。用羧基等位取代四唑环（60，IC50 = 68 nM）产生了有希望的新先导，随后对其进行了优化，以获得具有有效PARP-1 IC50值（4-197 nM）的类似物。PARP酶谱分析显示，大多数化合物对PARP-2具有选择性，其IC50值可与临床抑制剂媲美。与PARP-1结合的关键抑制剂的X射线晶体结构说明了与向PARP-1腺苷结合袋延伸的类似附件的相互作用方式。化合物81，一种同工型选择性PARP-1 / -2（IC50 = 30 nM / 2 nM）抑制剂，与同基因BRCA1精制细胞相比，对乳腺

  DOI：

  10.1021/acs.jmedchem.8b01709

文献信息

• Small-compound enhancers for functional O-mannosylation of alpha-dystroglycan, and uses thereof
  申请人：Wu Xiaohua

  公开号：US10221168B1

  公开（公告）日：2019-03-05

  The present invention provides compounds that can enhance functional O-mannosylation of proteins including alpha-dystroglycan. Also provided are methods of preparation of the compounds defined by the formula I. Also provided are the methods of using the compounds or the pharmaceutical acceptable salts or prodrugs thereof in treating and preventing subjects suffering from the diseases including muscular dystrophies and cancers.

  本发明提供了一种可以增强蛋白质的O-甘露糖基化功能，包括α-骨骼肌糖蛋白的化合物。还提供了一种按照式I定义的化合物的制备方法。同时提供了使用这些化合物或其药用可接受的盐或前药来治疗和预防患有包括肌肉萎缩症和癌症在内的疾病的方法。
• Small molecules enhance functional O-mannosylation of Alpha-dystroglycan
  作者：Fengping Lv、Zhi-fang Li、Wenhao Hu、Xiaohua Wu

  DOI：10.1016/j.bmc.2015.11.011

  日期：2015.12

  Alpha-dystroglycan (alpha-DG), a highly glycosylated receptor for extracellular matrix proteins, plays a critical role in many biological processes. Hypoglycosylation of alpha-DG results in various types of muscular dystrophies and is also highly associated with progression of majority of cancers. Currently, there are no effective treatments for those devastating diseases. Enhancing functional O-mannosyl glycans (FOG) of alpha-DG on the cell surfaces is a potential approach to address this unmet challenge. Based on the hypothesis that the cells can up-regulate FOG of alpha-DG in response to certain chemical stimuli, we developed a cell-based high-throughput screening (HTS) platform for searching chemical enhancers of FOG of alpha-DG from a large chemical library with 364,168 compounds. Sequential validation of the hits from a primary screening campaign and chemical works led to identification of a cluster of compounds that positively modulate FOG of alpha-DG on various cell surfaces including patient-derived myoblasts. These compounds enhance FOG of alpha-DG by almost ten folds, which provide us powerful tools for O-mannosylation studies and potential starting points for the development of drug to treat dystroglycanopathy. (c) 2015 Elsevier Ltd. All rights reserved.
• Discovery of imidazole carboxamides as potent and selective CCK1R agonists
  作者：Cheng Zhu、Alexa R. Hansen、Thomas Bateman、Zhesheng Chen、Tom G. Holt、James A. Hubert、Bindhu V. Karanam、Susan J. Lee、Jie Pan、Su Qian、Vijay B.G. Reddy、Marc L. Reitman、Alison M. Strack、Vincent Tong、Drew T. Weingarth、Michael S. Wolff、Doug J. MacNeil、Ann E. Weber、Joseph L. Duffy、Scott D. Edmondson

  DOI：10.1016/j.bmcl.2008.06.057

  日期：2008.8

  High-throughput screening revealed diaryl pyrazole 3 as a selective albeit modest cholecystokinin 1 receptor (CCK1R) agonist. SAR studies led to the discovery and optimization of a novel class of 1,2-diaryl imidazole carboxamides. Compound 44, which was pro. led extensively, showed good in vivo mouse gallbladder emptying (mGBE) and lean mouse overnight food intake (ONFI) reduction activities. (c) 2008 Elsevier Ltd. All rights reserved.
• From Cells to Mice to Target: Characterization of NEU-1053 (SB-443342) and Its Analogues for Treatment of Human African Trypanosomiasis
  作者：William G. Devine、Rosario Diaz-Gonzalez、Gloria Ceballos-Perez、Domingo Rojas、Takashi Satoh、Westley Tear、Ranae M. Ranade、Ximena Barros-Álvarez、Wim G. J. Hol、Frederick S. Buckner、Miguel Navarro、Michael P. Pollastri

  DOI：10.1021/acsinfecdis.6b00202

  日期：2017.3.10

  Human African trypanosomiasis is a neglected tropical disease that is lethal if left untreated. Existing therapeutics have limited efficacy and severe associated toxicities. 2-(2-(((3-((1H-Benzo[d]imidazol-2-yl)amino)propyl)amino)methyl)-4,6-dichloro-1H-indol-1-yl)ethan-1-ol (NEU-1053) has recently been identified from a high-throughput screen of >42,000 compounds as a highly potent and fast-acting trypanocidal agent capable of curing a bloodstream infection of Trypanosoma brucei in mice. We have designed a library of analogues to probe the structureactivity relationship and improve the predicted central nervous system (CNS) exposure of NEU-1053. We report the activity of these inhibitors of T. brucei, the efficacy of NEU-1053 in a murine CNS model of infection, and identification of the target of NEU-1053 via X-ray crystallography.